EICHOR
● Completed
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Condition: Locally Advanced or Metastatic Renal Cell Carcinoma · Sponsor: Ipsen
About this study
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (40)
| SALK - Salzburger Landesklinik | Salzburg, Austria | — |
| CHRU Besançon | Besançon, France | — |
| Centre Jean Perrin | Clermont-Ferrand, France | — |
| Centre Léon Bérard | Lyon, France | — |
| Institut Paoli Calmettes | Marseille, France | — |
| Institut de Cancérologie de Lorraine | Nancy, France | — |
| CHU de Nîmes - Institut de Cancérologie du Gard | Nîmes, France | — |
| Institut Mutualiste Montsouris | Paris, France | — |
| Centre Hospitalier Lyon Sud | Pierre-Bénite, France | — |
| Institut de Cancérologie de l'Ouest | Saint-Herblain, France | — |
| CHU Strasbourg | Strasbourg, France | — |
| Institut Claudius Régaud | Toulouse, France | — |
+ 28 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.